|
Comparison of our fT3 reference intervals to previously published reference intervals (2.5, 50 and 97.5%) of different age groups. |
|||||
| Soldin et al., 1995 Abbott IMx® |
Elmlinger et al., 2001 Immulite® |
Hübner et al., 2002 Advia Centaur® |
Kapelari et al., Advia Centaur® |
||
| Age |
|||||
| fT3 |
[pmol/L] |
[pmol/L] |
[pmol/L] |
[pmol/L] |
|
| n = 1,069 |
n = 762 |
n = 460 |
n = 1,295 |
||
|
|
|||||
| 1 d – 7 d |
2.2 – 7.4 |
2.76 – 6.91 – 11.67 |
2.32 – 8.11 a |
F: 5.00 – 6.60 – 7.50 |
|
| 8 – 15 d |
2.2 – 8.4 |
2.84 – 5.53 – 11.86 |
2.40 – 7.94 b |
M: 4.60 – 6.30 – 10.10 |
|
| 15 d – 1 m |
n.d. |
||||
| 1 – 12 m |
3.1 – 10.6 |
2.72 – 5.27 – 7.30 c |
F: 4.30 – 6.15 – 7.60 |
||
| M: 4.30 – 6.20 – 7.50 |
|||||
| 1 – 2 y |
3.28 – 6.08 – 11.06 |
3.05 – 5.63 – 6.93 |
F: 4.45 – 6.15 – 7.46 |
||
| 2 – 3 y |
M: 4.70 – 6.30 – 7.84 |
||||
| 3 – 4 y |
3.7 – 10.3 |
||||
| 4 – 5 y |
3.43 – 6.57 – 10.97 |
||||
| 5 – 6 y |
F: 4.60 – 6.20 – 7.30 |
||||
| 7 – 8 |
4.4 – 9.2 |
3.58 – 6.71 – 10.75 |
3.30 – 5.58 – 6.79 |
M: 4.80 – 6.10 – 7.20 |
|
| 9 – 10 |
3.72 – 6.44 – 10.87 |
||||
| 11 |
3.76 – 6.13 – 9.98 |
||||
| 12 |
3.76 – 5.88 – 8.86 |
3.46 – 5.54 – 6.7 |
F: 4.41 – 5.90 – 7.00 |
||
| 13 |
4.8 – 9.1 |
3.84 – 5.64 – 8.03 |
M: 4.90 – 6.00 – 7.00 |
||
| 14 |
3.81 – 5.45 – 7.28 |
||||
| 15 |
3.69 – 5.16 – 6.87 |
||||
| 16 |
3.61 – 4.98 – 6.88 |
3.57 – 5.33 – 6.65 |
F: 4.08 – 5.30 – 6.80 |
||
| 17 |
5.4 – 8.8 |
3.54 – 4.76 – 6.60 |
M: 4.60 – 5.80 – 7.10 |
||
| 18 – 19 |
3.52 – 4.65 – 6.30 |
||||
|
a 1 d – 3 d b 4 d – 30 d c 61 d – 12 m | |||||
Kapelari et al. BMC Endocrine Disorders 2008 8:15 doi:10.1186/1472-6823-8-15 |
|||||